Improved bioavailability of a micronized megestrol acetate tablet formulation in humans.
Megestrol acetate, a progestogen widely used in the palliative treatment of endometrial carcinoma and breast cancer, is currently administered orally as a solid dosage form. Bioavailability of the drug following oral administration is closely related to the effectiveness and safety profile of the drug in formulation. Improved immediate-release formulations should allow improved drug delivery into the systemic circulation and, at the end, to the site of action. The micronization of drugs is one of the technological procedures to achieve such a purpose. This paper reports the design and results obtained in an in vivo study of the bioavailability of a micronized megestrol acetate tablet formulation compared to a conventional form. A significant increase in the drug bioavailability was observed, in either the rate or the extent of absorption. In vitro dissolution data of the two study formulations reflected the in vivo findings.
Farinha
A
A
Laboratório de Estudos Farmacêuticos, Lisboa, Portugal. rcfarinha@mail.telepac.pt
Bica
A
A
Tavares
P
P
D000328:Adult; D018931:Antineoplastic Agents, Hormonal / Q000493:pharmacokinetics*; D001682:Biological Availability; D002626:Chemistry, Pharmaceutical; D016503:Drug Delivery Systems; D006801:Humans; D008297:Male; D019290:Megestrol Acetate / Q000493:pharmacokinetics*; D013607:Tablets
D018931:Antineoplastic Agents, Hormonal; D013607:Tablets; D019290:Megestrol Acetate